Dapiclermin

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameDapiclermin
Drug Alias NamePegAxokineCiliary neurotrophic factor - RegeneronAxokineRG-228RPN-228 +[7] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionCiliary neurotrophic factor receptor agonists
TargetsCiliary neurotrophic factor receptor
Therapy Area/IndicationsObesityAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRegeneron Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegeneron Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsObesityAmyotrophic Lateral Sclerosis

Other Information

ATC CodeN/A
Related LinksKEGG